David Tietjen, MD
Nephrology · Huntsville, ALNPI 1508838384
Payments from drug & device makers
Across 1,135 payments — averaging $2329.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$791K
- GSK$418K
- Boehringer Ingelheim International GmbH$357K
- Boehringer Ingelheim Pharma GmbH & Co.kg$315K
- Astrazeneca UK Limited$223K
- CSL Behring$189K
- plus $350K from 21 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 658 | $791,152 |
| GSK | 69 | $417,839 |
| Boehringer Ingelheim International GmbH | 31 | $357,217 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 44 | $315,459 |
| Astrazeneca UK Limited | 6 | $222,808 |
| CSL Behring | 126 | $189,419 |
| AstraZeneca(2 entities) | 33 | $180,476 |
| Boehringer Ingelheim | 10 | $89,598 |
| Amgen(2 entities) | 24 | $51,643 |
| Ardelyx, Inc. | 23 | $16,922 |
| Novartis | 14 | $6,971 |
| AbbVie | 1 | $2,065 |
| Vifor Pharma, Inc. | 19 | $515 |
| Otsuka America Pharmaceutical, Inc. | 19 | $341 |
| OPKO Pharmaceuticals, LLC | 18 | $290 |
| Calliditas Therapeutics US Inc. | 7 | $155 |
| Bayer | 5 | $122 |
| Aurinia Pharma U.S., Inc. | 4 | $97 |
| Travere Therapeutics, Inc. | 9 | $73 |
| Novo Nordisk | 3 | $68 |
| Daiichi Sankyo Inc. | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $44 |
| Fresenius USA Marketing, Inc. | 2 | $31 |
| Lilly USA, LLC | 1 | $20 |
| Shire North American Group Inc | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $15 |
How this compares
$2,643,423 in reported general payments places this provider in the 95th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Huntsville
- Michael QuadriniHuntsville$1.3M
- David BainsHuntsville$856K
- Carlo CastilloHuntsville$461K
- James SmelserHuntsville$172K
- Roger CoomerHuntsville$93K
- Todd BroomeHuntsville$7K
- Heather HaleyHuntsville$6K
- Saad RahmanHuntsville$6K
- Dana RizkBirmingham$2.6M
- Eric WallaceBirmingham$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.